Enjoy complimentary customisation on priority with our Enterprise License!
The cancer supportive care market is estimated to grow at a CAGR of 4.62% between 2022 and 2027. The scancer supportive care market size is forecast to increase by USD 6,563.92 million. The growth of the market depends on several factors, including the growing prevalence of cancer cases, many side effects associated with cancer treatment, and untapped potential in developing countries.
This cancer supportive care market report extensively covers market segmentation by therapeutic area (chemotherapy-induced anemia, chemotherapy-induced neutropenia, cancer pain, CINV, and others), distribution channel (hospitals pharmacies, drug stores and retail pharmacies, and online providers), and geography (North America, Europe, Asia, and Rest Of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
View the Bestselling Market Report sample Instantly
The growing prevalence of cancer cases is notably driving the market growth, although factors such as the rising popularity of targeted therapies for the treatment of cancer in developed countries may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Key Cancer Supportive Care Market Driver
The growing prevalence of cancer cases is notably driving market cancer supportive care drugs market growth. Cancer is one of the most common chronic diseases and is becoming a major health issue as it is increasing the mortality rate globally. Major factors that lead to cancer include genetic mutations, environmental factors such as tobacco smoking and pollution, and changing dietary patterns. The rising prevalence of these factors has directly contributed to the increased global incidence of cancer. As a result, cancer has become the second leading cause of death worldwide.
The population diagnosed with cancer, patients undergoing treatment, and mortality rate need to be registered to understand the trend of cancer in a country. Medical researchers need up-to-date data related to cancer to monitor trends and study the possible causes of cancer. Healthcare providers need data related to cancer incidences to make decisions regarding the volume of equipment and medicines to be purchased for treatment and to develop awareness and prevention programs. Therefore, the rising incidence and prevalence of cancer among the population are expected to increase the demand for cancer-supportive care hence, driving the growth of the market focus during the forecast period.
Significant Cancer Supportive Care Market Trends
The advent of biosimilars in cancer-associated treatment is the primary trend in the cancer supportive care drugs market. The growing demand for quality care has led to the increased use of erythropoietin drugs for the treatment of chemotherapy-induced anaemia. The majority of countries are under pressure to address this demand without increasing healthcare expenditure. Biosimilars will likely play a prominent role in this scenario, as, unlike generic drugs, they have the same active pharmaceutical ingredients as their originator biological compounds. Biosimilars are less expensive than biologics, thereby increasing accessibility. The patent expiry of biologics has led to the emergence of their biosimilars.
Epoetin alfa BS injection by JCR Pharmaceuticals and Kissei Pharmaceutical is a biosimilar version of Epoetin alfa. JCR Pharmaceuticals is also developing JR-013-sc Erythropoietin (which is under the Phase I stage of development) and JR-131 Darbopoietin (which is under the preclinical stage of development); both are of recombinant DNA origin. In addition, low-cost biosimilars are expected to affect the prices of branded drugs, thereby increasing the accessibility of drugs.
Major Cancer Supportive Care Market Challenge
The increasing preference for targeted therapies over chemotherapy drugs will hinder the growth prospects of the market. As there is an increased need to target specific molecules that are responsible for the growth of cancer, vendors are focusing on the development of targeted therapies, which have higher specificity than traditional chemotherapy drugs. Also, as chemotherapy drugs are associated with several side effects, researchers are conducting extensive R&D activities to better understand the disease's etiology and develop novel treatments.
Vendors are investing huge amounts to obtain approval for their cancer drugs. For instance, Boston-based Blueprint Medicines received clearance from the US FDA for its genetically targeted cancer therapy, Ayvakit, which is used for the treatment of gastrointestinal stromal tumours. Such market dynamics may hamper the global cancer-supportive care market growth.
Key Cancer Supportive Care Market Customer Landscape
The cancer supportive care market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Cancer Supportive Care Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Amgen Inc. - The company offers cancer-supportive care products such as Neulasta and Aranesp. This segment focuses on discovering, developing, manufacturing, and delivering innovative human therapeutics.
The cancer supportive care market report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
The reports categorize the global cancer supportive care market as a part of the global pharmaceuticals market within the overall healthcare industry. The parent global pharmaceuticals market covers products and companies engaged in R&D or production of generic drugs, non-generic drugs, and veterinary drugs. Our research report has extensively covered external factors influencing the parent market growth during the forecast period.
The market share growth of the chemotherapy-induced anemia segment will be significant during the forecast period. Anemia is a condition that develops when the blood lacks the required amount of healthy red blood cells or haemoglobin. Anemia is one of the most common types of side effects faced by individuals undergoing cancer treatment. Almost all individuals going through chemotherapy suffer mild anemia, and more than three-fourths of them develop more severe problems. As cancer cases are rising in developing countries as well, the higher adoption rate of chemotherapy will increase the demand for drugs indicated for chemotherapy-induced anemia, thereby driving market growth.
Get a glance at the market contribution of various segments Request a PDF Sample
The chemotherapy-induced anemia segment was valued at USD 6,133.38 million in 2017 and continued to grow until 2021. Cancer or chemotherapeutic drugs can cause anemia in an individual. Cancer suppresses erythropoiesis, leading to anemia. Chemotherapy targets fast-dividing cancer cells as well as healthy cells in the body. The cells in the bone marrow are highly sensitive to chemotherapy, resulting in the decreased production of red blood cells in the body. As the destruction of bone marrow is certain post-chemotherapy, the cases of anemia will rise in developed countries as well, thereby driving market growth.
For more insights on the market share of various regions Request PDF Sample now!
North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
North America holds the largest share of the global cancer-supportive care drugs market owing to the huge investments made in the oncology sector in the US. The US dominates the regional market and acts as the major revenue generator, followed by Canada. Huge investments in the pharmaceutical industry, specifically the oncology sector, and the presence of pharmaceutical giants in the region are some of the major factors backing the dominance of the US in the region as well as globally. Cancer is one of the most common chronic diseases in the US. Also, in every 100,000 population, 436 new cancer cases were reported, and about 156 died of cancer in the country in the same year. Thus, with the growing incidences of cancer, vendors will invest in extensive research to develop effective drugs for the treatment of several cancers. As cancer drugs are associated with several side effects, the demand for cancer-supportive care drugs is expected to increase in the region during the forecast period.
The outbreak of COVID-19 drastically affected the region, especially the US. However, with the initiation of vaccination drives in 2021, the number of COVID-19 cases decreased in the region, which led to the resumption of pharmaceutical industry operations. The rising number of cancer cases and the presence of well-established vendors for such products in this region will boost the growth of the cancer-supportive care market in the region during the forecast period.
The cancer supportive care market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
|
Cancer Supportive Care Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
175 |
|
Base year |
2022 |
|
Historic period |
2017-2021 |
|
Forecast period |
2023-2027 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 4.62% |
|
Market growth 2023-2027 |
USD 6,563.92 million |
|
Market structure |
Fragmented |
|
YoY growth 2022-2023(%) |
3.92 |
|
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
|
Performing market contribution |
North America at 39% |
|
Key countries |
US, Canada, UK, Germany, and China |
|
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
|
Key companies profiled |
Acacia Pharma Group Plc, Amgen Inc., Baxter International Inc., Bayer AG, Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., GlaxoSmithKline Plc, Helsinn Healthcare SA, Heron Therapeutics Inc., Johnson and Johnson, Kyowa Kirin Co. Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Purdue Pharma LP, RELIEF THERAPEUTICS Holding SA, Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Therapeutic Area
7 Market Segmentation by Distribution Channel
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Research Framework
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
INFORMATION SOURCES
Primary sources
Secondary sources
DATA ANALYSIS
Data Synthesis
Data Validation
REPORT WRITING
Qualitative
Quantitative
Certified ISO 9001 : 2015
We are ISO 9001:2015 recognized that ensures quality services and product delivery to our clients.
We are GDPR and CCPA compliant! Your transaction & personal information is protected from unauthorized use.
Get lifetime access to our
Technavio Insights
Customized Report as per your Business Needs
Let us help you make report more suited to your requirements.
Get the report (PDF) sent to your email within minutes.
